Identifying The Need A close examination of many drug products has
revealed low bioavailability of the active agent, due
to its poor aqueous solubility and a window of absorption.
This necessitates high and frequent dosing of active
agent to deliver and maintain adequate levels in the
blood plasma. Thus, there is a need of a dosage form
that makes the solubilised form of the drug available
at the site of absorption.
The Rubicon Research Achievement Rubicon Research's RubiRetenTM technology combines the
concepts of solubilisation and gastro-retention to increase
the bioavailability of active agents. A drug having
poor solubility is combined with a suitable solubiliser
and incorporated into a specifically designed gastro-retentive
system. The gastroretentivity is achieved by a suitable
combination of excipients that expand in an aqueous
media. This increases the size of the dosage form and
imparts buoyancy resulting in about six hours of gastric
residence in the fed state. This ensures that the solubilised
drug is released slowly and continuously in small quantities,
to trickle across the absorption window to maximise
its absorption.
The
System Performance
Intellectual Property
The RubiRetenTM technology is covered by pending patent
applications.
Key Attributes of RubiRetenTM
• Versatile with respect to the category of the
drug molecule
• Suitable with respect to drugs having different
doses
• Excipients employed are traditional and pharmacopoeial
• Conventional method of manufacture Benefits
• Improved bioavailability and better utilisation
of the drug
• Reduction in dose as well as frequency of dosing
• Better patient compliance
• Reduced adverse reactions
• Patient convenience in administering
